

STEP THERAPY POLICY

- POLICY:** Antidepressants – Serotonin and Norepinephrine Reuptake Inhibitors Step Therapy Policy
- Cymbalta® (duloxetine HCl delayed-release capsules – Lilly, generics)
 - Desvenlafaxine extended-release tablets (Alembic /Ranbaxy [brand product])
 - Drizalma Sprinkle™ (duloxetine delayed-release capsules – Sun Pharma)
 - Effexor® (venlafaxine HCl tablets – Wyeth, generics)
 - Effexor® XR (venlafaxine HCl extended-release capsules – Wyeth, generics)
 - Fetzima® (levomilnacipran HCl extended-release capsules – Forest)
 - Irenka™ (duloxetine 40 mg delayed-release capsules – Lupin, generic)
 - Khedezla™ (desvenlafaxine extended-release tablets – Osmotica/Macoven)
 - Pristiq® (desvenlafaxine succinate extended-release tablets – Wyeth, generics)
 - Savella® (milnacipran HCl tablets – Forest)
 - Venlafaxine HCl extended-release tablets (Upstate Pharma/Osmotica [brand product], generics)

REVIEW DATE: 02/17/2021; selected revision 04/07/2021

OVERVIEW

Desvenlafaxine, duloxetine, Fetzima, Khedezla, and venlafaxine are serotonin and norepinephrine reuptake inhibitors (SNRIs) indicated for the treatment of depression.¹⁻⁹ In addition, venlafaxine is indicated for the treatment of generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder. Duloxetine delayed-release capsules are indicated for the treatment of GAD, the management of neuropathic pain associated with diabetic peripheral neuropathy, the management of fibromyalgia, and the management of chronic musculoskeletal pain. Savella is only indicated for the management of fibromyalgia.¹⁰ While Savella is approved outside the US for major depressive disorder (MDD), it is not in development for this or any other indication in the US.

A venlafaxine extended-release *tablet* formulation is also available.⁵ This formulation does not carry the same indications as the capsule formulation (Effexor XR, generics). Venlafaxine extended-release tablets are indicated for MDD and social anxiety disorder. Equal doses of venlafaxine extended-release tablets are bioequivalent to venlafaxine extended-release *capsules* (Effexor XR, generics) when administered under fed conditions; however, these products are not AB-rated to each other. Similarly, in addition to desvenlafaxine succinate extended-release tablets (Pristiq, generics), branded Desvenlafaxine and Khedezla are available.^{4,7-9} Desvenlafaxine, desvenlafaxine succinate, and Khedezla are available in the same strength extended-release tablets, and share the same indication (treatment of MDD). Desvenlafaxine, Desvenlafaxine fumarate (discontinued), desvenlafaxine succinate, and Khedezla are not AB-rated to each other. However, efficacy studies conducted with desvenlafaxine succinate are cited in the Desvenlafaxine and Khedezla product information. Irenka was approved by the FDA as a generic to duloxetine delayed-release capsules (Cymbalta, generics). Irenka is being marketed as a branded product and has the same indications as duloxetine delayed-release capsules with the exception of fibromyalgia.¹¹ Lupin has also launched an authorized generic to Irenka. Drizalma Sprinkle relied on clinical efficacy studies for Cymbalta for approval and has the same indications as Cymbalta with the exception of a fibromyalgia indication.^{1,9}

The selective serotonin reuptake inhibitors (SSRIs) are a pharmacologic class of agents with antidepressant action and efficacy in the treatment of a wide range of mood and anxiety disorders that include obsessive compulsive disorder (OCD), panic disorder, social anxiety disorder (social phobia), posttraumatic stress disorder (PTSD), bulimia-nervosa, and GAD.¹² There are many off-label uses of the SSRIs and SNRIs in

a wide variety of psychiatric, as well as nonpsychiatric, conditions. It should be kept in mind that some patients may have a primary disorder, such as depression, and a comorbid condition, such as anxiety or sleep disorder, which may or may not affect response or the ability to tolerate adverse events (AEs).

INDICATIONS

All of the SNRIs (with the exception of Savella) are indicated for the treatment of MDD. Some of the SNRIs carry additional indications (Table 1). Table 2 provides the approved indications for the available SSRIs.

Table 1. FDA-Approved Indications for the SNRIs in Adults.¹⁻¹¹

Brand (generic)	MDD	GAD	Social Anxiety Disorder	Panic Disorder	DPN Pain	Chronic Musculoskeletal Pain	Fibro-myalgia
Cymbalta [®] (duloxetine delayed-release capsules, generics)	X	X [^]			X	X	X [*]
Desvenlafaxine extended-release tablets (Brand product)	X						
Drizalma Sprinkle [™] (duloxetine delayed-release capsules)	X	X [^]			X	X	
Effexor [®] (venlafaxine immediate-release tablets, generics)	X						
Effexor XR [®] (venlafaxine extended-release capsules, generics)	X	X	X	X			
Fetzima [™] (levomilnacipran extended-release capsules)	X						
Irenka [™] (duloxetine 40 mg delayed-release capsules)	X	X [^]			X	X	
Khedezla [™] (desvenlafaxine extended-release tablets)	X						
Pristiq [®] (desvenlafaxine succinate extended-release tablets, generics)	X						
Savella [®] (milnacipran tablets)							X
Venlafaxine extended-release tablets (Brand product, generics)	X		X				

SNRI – Serotonin norepinephrine reuptake inhibitor; MDD – Major depressive disorder; GAD – Generalized anxiety disorder; DPN – Diabetic peripheral neuropathy; [^] Efficacy studied in patients ≥ 7 years of age with GAD; ^{*} Approved for use in patients ≥ 13 years of age.

Table 2. FDA-Approved Indications for the SSRIs.¹³⁻²⁵

Brand (generic)	MDD	OCD	Panic Disorder	Bulimia Nervosa	PTSD	Social Anxiety Disorder	GAD	PMDD	VMS
Celexa [®] (citalopram tablets and oral solution, generics)	X								
Lexapro [®] (escitalopram tablets and oral solution, generics)	X ^α						X		
Prozac [®] (fluoxetine capsules, tablets, and oral solution, generics)	X [†]	X [†]	X	X					
Prozac [®] Weekly [™] (fluoxetine delayed-release capsules, generics)	X [*]								
Sarafem [®] (fluoxetine capsules and tablets, generics)								X	
Fluvoxamine (generics only)		X [†]							
Luvox CR [®] (fluvoxamine extended-release capsules, generics)		X [†]							
Paxil [®] (paroxetine HCl tablets and oral suspension, generics)	X	X	X		X	X	X		
Paxil CR [®] (paroxetine HCl controlled-release tablets, generics)	X		X			X		X	
Pexeva [®] (paroxetine mesylate tablets)	X	X	X				X		
Brisdelle [™] (paroxetine 7.5 mg capsules)									X
Zoloft [®] (sertraline tablets and oral suspension, generics)	X	X [†]	X		X	X		X	
Viibryd [®] (vilazodone tablets)	X								
Trintellix [™] (formerly Brintellix [®]) [vortioxetine tablets]	X								

SSRI – Selective serotonin reuptake inhibitor; MDD – Major depressive disorder; OCD – Obsessive compulsive disorder; PTSD – Posttraumatic stress disorder; GAD – Generalized anxiety disorder; PMDD – Premenstrual dysphoric disorder; VMS – Vasomotor symptoms; ^α FDA-approved indication includes adolescents 12 to 17 years of age; [†] FDA-approved indication includes children and adolescents; * Approved for the prevention of relapse during the continuation treatment phase of depression; CR – Controlled release; HCl – Hydrochloride.

POLICY STATEMENT

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product (other than Savella). In addition, this program encourages the use of two Products from Step 1 and/or Step 2 prior to the use of Savella. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

Automation: A patient with a history of one Step 1 Product within the 130-day look-back period is excluded from Step Therapy (other than Savella). A patient with a history of two Products from Step 1 and/or Step 2 within the 130-day look-back period is excluded from Step Therapy for Savella. Patients > 18 years of age are targeted in this Step Therapy program.

Step 1: citalopram tablets (Celexa, generic), generic citalopram oral solution, generic duloxetine delayed-release 20 mg, 30 mg, 60 mg capsules, escitalopram tablets (Lexapro, generic), escitalopram oral solution (Lexapro, generic), fluoxetine immediate-release capsules and tablets (Prozac, Sarafem, generic), generic fluoxetine oral solution, fluoxetine delayed-release capsules (Prozac Weekly, generics), generic fluvoxamine immediate-release tablets, generic fluvoxamine extended-release capsules (Luvox CR, generics), paroxetine HCl immediate- and controlled-release tablets (Paxil, Paxil CR, generic), paroxetine oral suspension (Paxil, generic), Pexeva, sertraline tablets (Zoloft, generic), sertraline oral solution (Zoloft, generic), Trintellix (formerly Brintellix), Viibryd, generic venlafaxine immediate-release tablets, generic venlafaxine extended-release capsules

Step 2: Cymbalta, Desvenlafaxine extended-release tablets (brand product), Drizalma Sprinkle, Effexor, Effexor XR, Fetzima, Irenka, Khedezla, Pristiq, Savella, Venlafaxine extended-release tablets (brand product), generic desvenlafaxine succinate extended-release tablets, generic duloxetine 40 mg delayed-release capsules, generic venlafaxine extended-release tablets

CRITERIA

1. If the patient has tried one Step 1 Product, approve a Step 2 Product (other than Savella).
2. If the patient has tried at least two Products from Step 1 and/or Step 2 (other than Savella), approve Savella.
3. If the patient is being treated for fibromyalgia (with or without depression) and the patient has tried duloxetine delayed-release capsules (brand or generic), approve Savella.
4. If the patient is currently taking or has taken brand name Desvenlafaxine extended-release tablets, desvenlafaxine succinate extended-release tablets (Pristiq or generics), Khedezla, or Fetzima at any time in the past and discontinued its use, approve the Product that they have used.
5. If the patient has suicidal ideation, approve Desvenlafaxine extended-release tablets, desvenlafaxine succinate extended-release tablets (Pristiq or generics), Khedezla, or Fetzima.

REFERENCES

1. Cymbalta[®] capsules [prescribing information]. Indianapolis, IN: Eli Lilly and Company; May 2020.
2. Effexor XR[®] extended-release capsules [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2017.
3. Effexor[®] tablets [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2012.
4. Pristiq[®] extended-release tablets [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; February 2018.
5. Venlafaxine extended-release tablets [prescribing information]. Marietta, GA: Osmotica Pharmaceutical; November 2017.
6. Fetzima[®] extended-release capsules [prescribing information]. Irvine, CA: Allergan USA, Inc.; October 2019.
7. Khedezla[™] extended-release tablets [prescribing information]. Marietta, GA: Osmotica Pharmaceutical US LLC; January 2019.
8. Desvenlafaxine extended-release tablets [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; November 2019.
9. Drizalma Sprinkle[™] delayed-release capsules [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; July 2020.
10. Savella[®] tablets [prescribing information]. Irvine, CA: Allergan USA, Inc.; November 2017.
11. Irenka[™] capsules [prescribing information]. Baltimore, MD: Lupin Pharma; June 2015.

12. Facts and Comparisons® eAnswers. Wolters Kluwer UpToDate, Inc.; 2021. Available at: <http://fco.factsandcomparisons.com/lco/action/home>. Accessed on February 10, 2021. Search terms: SSRIs, SNRIs.
13. Prozac® capsules, Prozac® Weekly™ capsules [prescribing information]. Indianapolis, IN: Eli Lilly and Company; April 2020.
14. Paxil® tablets and oral suspension [prescribing information]. Weston, FL: Apotex Corp.; February 2021.
15. Zoloft® tablets, oral concentrate [prescribing information]. New York, NY: Pfizer Laboratories; December 2017.
16. Celexa® tablets and oral solution [prescribing information]. Irvine, CA: Allergan USA, Inc.; January 2019.
17. Paxil CR® controlled-release tablets [prescribing information]. Weston, FL: Apotex Corp.; September 2019.
18. Lexapro® tablets and oral solution [prescribing information]. Irvine, CA: Allergan USA, Inc.; August 2020.
19. Pexeva® tablets [prescribing information]. Roswell, GA: Sebela Pharmaceutical Inc.; December 2020.
20. Fluvoxamine maleate tablets [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc.; December 2019.
21. Sarafem® capsules [prescribing information]. Irvine, CA: Allergan USA, Inc.; January 2017.
22. Luvox CR® extended-release capsules [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; January 2017.
23. Viibryd® tablets [prescribing information]. Madison, NJ: Allergan USA, Inc.; January 2020.
24. Trintellix™ (formerly Brintellix® tablets) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc and Lundbeck; January 2021.
25. Brisdelle® capsules [prescribing information]. Roswell, GA: Sebela Pharmaceuticals Inc.; April 2017.